Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors

Report on the Study of Cardiac Dysfunction Among Breast Cancer Survivors Academic Background Breast cancer is the most common cancer diagnosed in women. Advances in early detection and novel therapeutics have yielded 5-year survival rates exceeding 90%. However, with over four million breast cancer survivors in the United States today, the quality ...

Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice

Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice Academic Background The cardiovascular health (CVH) of cancer survivors has become an increasingly important concern. Studies have shown that cancer survivors generally have poorer cardiovascular health, partly due to th...

Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery

The Impact of a Statewide Regionalization Policy on Travel Distance for Initial Breast Cancer Surgery Academic Background Breast cancer is one of the most common cancers among women globally, and the quality of treatment and patient survival rates are closely related to the allocation of medical resources. Studies have shown that high-volume medica...

Single or Double Induction with 7+3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DAUNODouble Trial by the Study Alliance Leukemia

Academic Background Acute Myeloid Leukemia (AML) is a malignant blood disorder, with the core of its treatment being induction chemotherapy, typically involving a combination of cytarabine and anthracyclines (such as daunorubicin). Although this treatment regimen has been in use since the 1980s, questions regarding the optimal dose of daunorubicin ...

Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia: Efficacy and Safety

Academic Background Acute leukemia is a malignant hematologic disease caused by genetic mutations in hematopoietic cells, characterized by a block in differentiation during hematopoiesis and uncontrolled cellular proliferation. Among these, KMT2A gene rearrangements (KMT2A-rearranged, KMT2Ar) occur in up to 10% of acute leukemias in children and ad...

Efficacy and Safety of Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase III ARANOTE Trial Academic Background Metastatic hormone-sensitive prostate cancer (mHSPC) is a common type of prostate cancer. Patients typically respond to androgen-deprivation therapy (ADT) for a period of ti...

Whole Lung Irradiation in Rhabdomyosarcoma with Lung Metastases: A Report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group

Efficacy of Whole Lung Irradiation in Rhabdomyosarcoma with Lung Metastases Academic Background Rhabdomyosarcoma (RMS) is a common soft tissue sarcoma in children. Despite advancements in treatment, the prognosis for patients with metastatic RMS remains poor, especially for those with lung metastases, whose survival rates are significantly lower th...

Revumenib Revises the Treatment Landscape for KMT2A-R Leukemia

Revumenib Alters the Treatment Landscape for KMT2A-Rearranged Leukemia Academic Background Leukemia is a malignant disease caused by abnormalities in the hematopoietic system, with KMT2A-rearranged (KMT2A-r) leukemia being a common subtype, particularly in pediatric and adult acute myeloid leukemia (AML). Rearrangements of the KMT2A gene (lysine me...

Psychological Intervention for Caregivers of Patients with Primary Malignant Brain Tumors

Academic Background Caregivers of patients with Primary Malignant Brain Tumors (PMBT) face significant psychological distress. PMBT is not only an incurable cancer but also accompanied by degenerative neurological conditions, leading caregivers to cope with the gradual loss of the patient’s physical functions and irreversible changes in personality...

Efficacy of Cediranib and Olaparib Combination in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer

Academic Background and Problem Statement Epithelial Ovarian Cancer (EOC) remains one of the leading causes of death among gynecologic malignancies. Although the incorporation of molecularly targeted therapies, such as bevacizumab and PARP inhibitors, has improved Progression-Free Survival (PFS) and, in some cases, Overall Survival (OS), many patie...